we add

The European Regional Agenda, Science and Innovation

The HealthTIES answersHealthTIES is an EU funded Regions of Knowledge for health program

we add

Content

HealthTIES context

- Regional innovative ecosystems

- Health challenges in the 21st Century

HealthTIES Regions of Knowledge project 2010 – 2013

- Approach

- Midterm results

- Outlook 2012-2013

we add

HealthTIES context

we add

Science-Innovation roadmaps

Lisbon-Agenda

Europe 2020; Flagship Initiative

Innovation Union

Europe Finance perspective 2014-2024

European Research Management

From project approach to program and region approach

All focussing on creating a competitive European Research Area

we add

Common Strategic Framework

Science for innovation (individual research group)

Innovation for society (social demands)

Innovation for competitiveness (industry)

Focus, mass, social and economic impact

we add

EU innovation weaknesses

Underinvestment in our knowledge foundation

Unsatisfactory framework conditions

- access to finance

- high IPR costs

- slow standardisation

- ineffective use of public procurement

To much fragmentation and costly duplicationSource: Europe 2020

we add

Contemporary healthcare Challenges and Opportunities

How do we improve medical care so as to live longer, healthier lives?

How do we provide affordable medical care for the individual and the

society?

Where do we find the trained people who will provide healthcare?

How do we guarantee the quality and safety of our medical care?

How can we use the “answers” to these questions to provide economic

opportunities?

we add

HealthTIES project

we add

HealthTIES regions are

Strong European regions in

Life science &

Medical technology

Both

Scientific &

Industrial

we add

The HealthTIES approach

Modeling

Fact Finding

Virtual Reference Region

Analysis

SWOT

Joint

Action

Plan

Monitoring over years to come

we add

Spin off companies

Business Development

Patents

Facilities / Infrastructure

Modeling the ecosystem – WP2

Input

Research funding

Knowledge

R&D Infrastructure

Human Capital

output

Companies

Capital

Products

Jobs

Innovation system

we add

Data gathering of ecosystem – WP3Approach

Open sources for input and output

“We all have pieces of the puzzle”

Data needs to be reproducible

Balance relevance vs accuracy

we add

Data gathering ecosystem – WP3parameters

Input Innovation System Output

Profs H-factor >30 University spin-offs FTEs Biotech companies

Publications Granted US patents Biotech companies < and > 20 FTEs

Research funding WAIT indicator for countries Big trade sales

Internat./nat. grad. MSc students Big public-private projects Products on market

Internat./nat. PhD students TTO FTEs Products clinical trials

Junior/senior ERC grants Nat. govern. innov. support Products discovery phase

Research m2 Nat. attractiveness (WEF index) Medicines available in countries

Research hosptial beds Science parks m2 Total/number investments

Clinical trials phase I and II Science parks support FTEs Average Series A investments

we add

Benchmarking and best practices

Based upon key figures +

Visits to each others

- scienceparks,

- universities,

- incubators etc.

we add

Virtual Reference Regionwww.vrr.healthties.eu

we add

Strengths Weaknesses Opportunities Threats

Strengths

Excellent research environment

Good numbers of ERC grants and joint research projects

High investment levels

Good numbers of granted US patents

Weaknesses

Small, fragmented bioscience parks

Low numbers of research students

Few research hospital beds and clinical trials

Opportunities

Improve innovation system

Capitalise on US patents

Increase start-ups and attract more companies

Improve job opportunities

Improve discovery and availability of medicines

Threats

Adverse economic environments

TTOs not maiximising their effectiveness for all stakeholders

we add

Research and Development Strength - WP4

Science via Web of Knowledge & Network

Industry via Biotechgate.com & Network

we add

Outcomes WP412 detailed research group collectionson matrix crossroads

Benchmark Web of Knowledge strengths

we add

Analysis and best practices result in regional and joint actions

Regional actions

Bench mark results

Region 1 Region 5Region 4Region 3Region 2

Joint actionsHealthTIES – X

EU regions in health innovation

we add

Actions following from analyses Themes are

1. Innovation ecosystem

business development, incubator cooperation, investment fund, clinical

trial portal

2. Research, technology, development agenda

disseminate gained insights, increase joint RTD projects, smart

specialisation strategy, exchange of (teaching) staff etc.

3. Dissemination, increasing the participation of others

Keep involving our own regional stakeholders during JAP phase, promote

the VRR during conferences, actively invite other regions to use it, keep

improving the model

we add

Joint Action Plan WP5/6Structure example

Barcelona Debrecen Medical Delta Oxford Zurich

Joint Action 1Combining clinical trials

participant participant participant participant Leader

Joint Action 2Joint R&D projects

participant participant participant leader Participant

Regional action 1Setup incubator

Already present

- Already present. Advisor

Local leader

Already present. Advisor

Regional action 2Increase ERC grants

- Local leader Local leader advisor advisor

Joint Action Plan is under construction. Examples do not reflect the actual situation.

we add

JAP realization - formatProject: [Title] Project coordinator: [Name + organisation]

Description [Aim of the project + rationale (based upon analysis)]

Result in 2013

Others involved [names + organisations, from own region + from other HealthTIES regions if applicable]

HealthTIES region with Best Practice

[Region + name best practice]

Approach [Describe the main and visible actions results in period 2012-2013, the budget origin and involvement of experts etc.]

we add

Backup

we add

Industry in Medical Deltacurrent status in www.biotechgate.com

300 companies

18.000 industrial jobs

140 products on market

85 in development

we add

HealthTIES key PeopleDaily Board

Hans Goossens (Province of South Holland, coordinator)

Pancras Hogendoorn (LUMC, Scienctific director)

Roel Kamerling (Medical Delta / TU Delft, managing director

Laura Vis (Province of South Holland, Secretary Daily Board)

Executive Committee (= work package leaders + daily board)

Nerea Alonso (BioCat)

Bass Hassan and Laurel Edmunds (Oxford University)

Ernst Hafen and Silvia Gluderer (ETH Zurich)

Máté Rab and Brigitta Máté (Debrecen University)

In consortium board for Medical Delta

Henri Lenferink (Mayor of Leiden)

Huib Pols, dean of the Erasmus Medical Centre)

we add

Input results WP3

we add

Input results WP3

we add

Innovation system results WP3

we add

Innovation system results WP3

we add

Output results WP3

we add

Output results WP3

we add

Biocat

we add

Strengths

High availability of scientific profiles in life sciences

Good programmes attracting foreign excellent scientist

Important network of research hospi. performing clinical trials

High density of incubators

Weaknesses

Scarce phase 3/4 investm.

Lack of financial support at level of ideas

Duplication of equipment

Insufficient big PPPs

Weak valorisation structure in hospitals

Opportunities

Public procurement for innovations framework

European programmess for boosting public-private partnerships

Creation of new sectorial VC funds

Threats

Intensified debate on healthcare systems sustainability

Relocation of big pharma R&D structures

Difficulties to adapt to new market paradigms

Biocat

we add

Debrecen

we add

Strengths

Governmental innovation support

Many clinical trials in phase I and II

Attractive region for investors

Many full-time employees

Weaknesses

Little research, incubator and science park infrastructure

Few big PPPs

Small qualified support staff

Few biotech companies

Few internat. renowned profs, few internat. students

Opportunities

Public procurement for innovations framework

European programmess for boosting public-private partnerships

Creation of new sectorial VC funds

Threats

Intensified debate on healthcare systems sustainability

Relocation of big pharma R&D structures

Difficulties to adapt to new market paradigms

Debrecen

we add

Medical Delta

we add

Medical Delta

we add

Oxford

we add

Oxford

we add

Zurich

we add

Zurich

we add

Input

Innovation system

Output

Products

we add

Worldwide context